Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study
Talquetamab, a G protein-coupled receptor class C group 5 member D-targeting bispecific antibody for relapsed/refractory multiple myeloma (R/R MM), plus daratumumab, may lead to deeper and more durable responses than either therapy alone. In the phase 1b TRIMM-2 study, patients with R/R MM (at least...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
December 11 2025
|
| In: |
Blood
Year: 2025, Volume: 146, Issue: 24, Pages: 2902-2913 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood.2025029360 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.2025029360
|
| Author Notes: | Ajai Chari, Niels W.C.J. van de Donk, Bhagirathbhai Dholaria, Katja Weisel, María-Victoria Mateos, Hartmut Goldschmidt, Thomas G. Martin, Daniel Morillo, Donna Reece, Paula Rodríguez-Otero, Manisha Bhutani, Anita D’Souza, Albert Oriol, Laura Rosiñol, Nizar J. Bahlis, Deeksha Vishwamitra, Sheri Skerget, Raluca I. Verona, Kalpana Bakshi, Lijuan Kang, Thomas J. Prior, Lien Vandenberk, Jaszianne Tolbert, Sangmin Lee, M. Damiette Smit, Ralph Wäsch |
MARC
| LEADER | 00000naa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1961855828 | ||
| 003 | DE-627 | ||
| 005 | 20260220094518.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260220s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2025029360 |2 doi | |
| 035 | |a (DE-627)1961855828 | ||
| 035 | |a (DE-599)KXP1961855828 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Chari, Ajai |e VerfasserIn |0 (DE-588)1201319528 |0 (DE-627)1684861276 |4 aut | |
| 245 | 1 | 0 | |a Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study |c Ajai Chari, Niels W.C.J. van de Donk, Bhagirathbhai Dholaria, Katja Weisel, María-Victoria Mateos, Hartmut Goldschmidt, Thomas G. Martin, Daniel Morillo, Donna Reece, Paula Rodríguez-Otero, Manisha Bhutani, Anita D’Souza, Albert Oriol, Laura Rosiñol, Nizar J. Bahlis, Deeksha Vishwamitra, Sheri Skerget, Raluca I. Verona, Kalpana Bakshi, Lijuan Kang, Thomas J. Prior, Lien Vandenberk, Jaszianne Tolbert, Sangmin Lee, M. Damiette Smit, Ralph Wäsch |
| 246 | 3 | 0 | |a two |
| 264 | 1 | |c December 11 2025 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 20.02.2026 | ||
| 520 | |a Talquetamab, a G protein-coupled receptor class C group 5 member D-targeting bispecific antibody for relapsed/refractory multiple myeloma (R/R MM), plus daratumumab, may lead to deeper and more durable responses than either therapy alone. In the phase 1b TRIMM-2 study, patients with R/R MM (at least 3 previous lines of therapy or double refractory to a proteasome inhibitor and an immunomodulatory drug) received subcutaneous talquetamab 0.4 mg/kg weekly (QW; “QW cohort”) or 0.8 mg/kg every other week (Q2W cohort) plus daratumumab 1800 mg per the approved schedule. The primary end point was safety. Secondary end points included overall response and duration of response. Progression-free survival was an exploratory end point. Sixty-five patients (median 5 previous lines of therapy; 61.5% triple-class refractory; 24.6% bispecific antibody exposed) received talquetamab plus daratumumab (QW, n = 14; Q2W, n = 51; median follow-up of 18.6 months). Most common adverse events were oral events, skin events, cytokine release syndrome, and infections. Grade 3 or 4 events occurred in 81.5%. Two patients had dose-limiting toxicities, both in the Q2W cohort (grade 3 stomatitis/oral mucositis, and grade 3 maculopapular rash). Responses occurred in 71.4% (QW cohort) and 82.4% (Q2W cohort) of patients. Median progression-free survival was 23.3 and 21.2 months, respectively, in each cohort. Pharmacodynamic results suggest the immunomodulatory action of daratumumab contributes to a conducive environment for talquetamab by reducing immunosuppressive cells. Talquetamab plus daratumumab demonstrated promising efficacy outcomes in patients with heavily pretreated disease, with a safety profile consistent with each agent as monotherapy. This trial was registered at www.clinicaltrials.gov as #NCT04108195. | ||
| 700 | 1 | |a van de Donk, Niels W. C. J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dholaria, Bhagirathbhai |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weisel, Katja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mateos, María-Victoria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Martin, Thomas G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Morillo, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reece, Donna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rodríguez-Otero, Paula |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bhutani, Manisha |e VerfasserIn |4 aut | |
| 700 | 1 | |a D’Souza, Anita |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oriol, Albert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rosiñol, Laura |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bahlis, Nizar J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vishwamitra, Deeksha |e VerfasserIn |4 aut | |
| 700 | 1 | |a Skerget, Sheri |e VerfasserIn |4 aut | |
| 700 | 1 | |a Verona, Raluca I. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bakshi, Kalpana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kang, Lijuan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Prior, Thomas J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vandenberk, Lien |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tolbert, Jaszianne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lee, Sangmin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Smit, M. Damiette |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wäsch, Ralph |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d Washington, DC : American Society of Hematology, 1946 |g 146(2025), 24 vom: Dez., Seite 2902-2913 |h Online-Ressource |w (DE-627)266886647 |w (DE-600)1468538-3 |w (DE-576)075961938 |x 1528-0020 |7 nnas |a Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study |
| 773 | 1 | 8 | |g volume:146 |g year:2025 |g number:24 |g month:12 |g pages:2902-2913 |g extent:12 |a Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study |
| 856 | 4 | 0 | |u https://doi.org/10.1182/blood.2025029360 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |7 1 |
| 951 | |a AR | ||
| 992 | |a 20260220 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 999 | |a KXP-PPN1961855828 |e 4920519508 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study","title_sort":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study"}],"language":["eng"],"id":{"eki":["1961855828"],"doi":["10.1182/blood.2025029360"]},"physDesc":[{"extent":"12 S."}],"recId":"1961855828","relHost":[{"title":[{"subtitle":"journal of the American Society of Hematology","title_sort":"Blood","title":"Blood"}],"language":["eng"],"id":{"eki":["266886647"],"zdb":["1468538-3"],"issn":["1528-0020"]},"physDesc":[{"extent":"Online-Ressource"}],"corporate":[{"role":"isb","display":"American Society of Hematology"}],"recId":"266886647","disp":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 studyBlood","pubHistory":["1.1946 -"],"titleAlt":[{"title":"Blood online"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 21.04.2023"],"origin":[{"publisher":"American Society of Hematology ; Saunders ; HighWire Press","dateIssuedDisp":"1946-","publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif.","dateIssuedKey":"1946"}],"part":{"pages":"2902-2913","extent":"12","volume":"146","year":"2025","text":"146(2025), 24 vom: Dez., Seite 2902-2913","issue":"24"}}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"given":"Ajai","family":"Chari","display":"Chari, Ajai","role":"aut"},{"display":"van de Donk, Niels W. C. J.","role":"aut","given":"Niels W. C. J.","family":"van de Donk"},{"role":"aut","display":"Dholaria, Bhagirathbhai","family":"Dholaria","given":"Bhagirathbhai"},{"role":"aut","display":"Weisel, Katja","given":"Katja","family":"Weisel"},{"role":"aut","display":"Mateos, María-Victoria","family":"Mateos","given":"María-Victoria"},{"given":"Hartmut","family":"Goldschmidt","display":"Goldschmidt, Hartmut","role":"aut"},{"given":"Thomas G.","family":"Martin","display":"Martin, Thomas G.","role":"aut"},{"given":"Daniel","family":"Morillo","display":"Morillo, Daniel","role":"aut"},{"role":"aut","display":"Reece, Donna","given":"Donna","family":"Reece"},{"display":"Rodríguez-Otero, Paula","role":"aut","given":"Paula","family":"Rodríguez-Otero"},{"display":"Bhutani, Manisha","role":"aut","family":"Bhutani","given":"Manisha"},{"role":"aut","display":"D’Souza, Anita","given":"Anita","family":"D’Souza"},{"display":"Oriol, Albert","role":"aut","given":"Albert","family":"Oriol"},{"family":"Rosiñol","given":"Laura","display":"Rosiñol, Laura","role":"aut"},{"family":"Bahlis","given":"Nizar J.","role":"aut","display":"Bahlis, Nizar J."},{"role":"aut","display":"Vishwamitra, Deeksha","family":"Vishwamitra","given":"Deeksha"},{"given":"Sheri","family":"Skerget","display":"Skerget, Sheri","role":"aut"},{"family":"Verona","given":"Raluca I.","display":"Verona, Raluca I.","role":"aut"},{"given":"Kalpana","family":"Bakshi","display":"Bakshi, Kalpana","role":"aut"},{"given":"Lijuan","family":"Kang","role":"aut","display":"Kang, Lijuan"},{"role":"aut","display":"Prior, Thomas J.","given":"Thomas J.","family":"Prior"},{"role":"aut","display":"Vandenberk, Lien","given":"Lien","family":"Vandenberk"},{"given":"Jaszianne","family":"Tolbert","role":"aut","display":"Tolbert, Jaszianne"},{"family":"Lee","given":"Sangmin","display":"Lee, Sangmin","role":"aut"},{"family":"Smit","given":"M. Damiette","role":"aut","display":"Smit, M. Damiette"},{"given":"Ralph","family":"Wäsch","display":"Wäsch, Ralph","role":"aut"}],"note":["Gesehen am 20.02.2026"],"origin":[{"dateIssuedDisp":"December 11 2025","dateIssuedKey":"2025"}],"name":{"displayForm":["Ajai Chari, Niels W.C.J. van de Donk, Bhagirathbhai Dholaria, Katja Weisel, María-Victoria Mateos, Hartmut Goldschmidt, Thomas G. Martin, Daniel Morillo, Donna Reece, Paula Rodríguez-Otero, Manisha Bhutani, Anita D’Souza, Albert Oriol, Laura Rosiñol, Nizar J. Bahlis, Deeksha Vishwamitra, Sheri Skerget, Raluca I. Verona, Kalpana Bakshi, Lijuan Kang, Thomas J. Prior, Lien Vandenberk, Jaszianne Tolbert, Sangmin Lee, M. Damiette Smit, Ralph Wäsch"]}} | ||
| SRT | |a CHARIAJAIVTALQUETAMA1120 | ||